Display options
Cite
Vasou O, Skagias L, Anastasia M, et al. Detection of pAkt protein in imprint cytology of invasive breast cancer: Correlation with HER2/neu, hormone receptors, and other clinicopathological variables. Cytojournal. 2015;12:6doi: 10.4103/1742-6413.153965.
Vasou, O., Skagias, L., Anastasia, M., Paulina, A., Patsouris, E., & Politi, E. (2015). Detection of pAkt protein in imprint cytology of invasive breast cancer: Correlation with HER2/neu, hormone receptors, and other clinicopathological variables. CytoJournal, 126. https://doi.org/10.4103/1742-6413.153965
Vasou, Olympia, et al. "Detection of pAkt protein in imprint cytology of invasive breast cancer: Correlation with HER2/neu, hormone receptors, and other clinicopathological variables." CytoJournal vol. 12 (2015): 6. doi: https://doi.org/10.4103/1742-6413.153965
Vasou O, Skagias L, Anastasia M, Paulina A, Patsouris E, Politi E. Detection of pAkt protein in imprint cytology of invasive breast cancer: Correlation with HER2/neu, hormone receptors, and other clinicopathological variables. Cytojournal. 2015 Mar 25;12:6. doi: 10.4103/1742-6413.153965. eCollection 2015. PMID: 25838835; PMCID: PMC4382762.
Copy Download .nbib Format: NLM
Share it on

Cytojournal. 2015 Mar 25;12:6. doi: 10.4103/1742-6413.153965. eCollection 2015.

Detection of pAkt protein in imprint cytology of invasive breast cancer: Correlation with HER2/neu, hormone receptors, and other clinicopathological variables.

CytoJournal

Olympia Vasou, Lazaros Skagias, Margariti Anastasia, Athanasiadou Paulina, Efstratios Patsouris, Ekaterini Politi

Affiliations

  1. Address: Department of Cytopathology, Aretaieion University Hospital, Athens, Greece, Europe.
  2. Department of Cytopathology, 424 General Army Hospital, Thessaloniki, Greece, Europe.
  3. Department of Pathology, Mitera General Hospital and Maternity Clinic, Athens, Greece, Europe.
  4. Department of Pathology, Medical School, University of Athens, Athens, Greece, Europe.

PMID: 25838835 PMCID: PMC4382762 DOI: 10.4103/1742-6413.153965

Abstract

PURPOSE: Akt is a serine/threonine protein kinase and has emerged as a crucial regulator of widely divergent cellular processes, including apoptosis, proliferation, differentiation, and metabolism. Activation of Akt/protein kinase B has been positively associated with human epidermal growth-factor receptor 2 (HER2)/neu overexpression in breast carcinoma and a worse outcome among endocrine treated patients. The Akt signaling pathway currently attracts considerable attention as a new target for effective therapeutic strategies. We therefore investigated the relationship between activation of Akt and clinicopathologic variables including hormone receptor and HER2/neu status.

METHODS: Archival tumor tissues from 100 patients with invasive breast carcinoma were analyzed by immunocytochemistry. This study describes the results of immunocytochemical pAkt expression in breast carcinoma imprints, prepared from cut surfaces of freshly removed tumors. Both nuclear and cytoplasmic expressions were evaluated for pAkt.

RESULTS: Nuclear and cytoplasmic positive scores of 72% (72/100) and 42% (42/100), respectively, were found. Coexistence of nuclear and cytoplasmic staining was observed in 32 cases (32/100). Nuclear positive staining correlated with HER2/neu overexpression (P = 0.043) and was significantly associated with positive involvement of axillary lymph nodes (P = 0.013). No correlation was found between cytoplasmic pAkt rate and clinicopathological parameters, estrogen receptor, progesterone receptor or HER2/neu expression.

CONCLUSIONS: pAkt expression can be evaluated in cytological material and may add valuable information to current prognostic models for breast cancer. pAkt overexpression appears to be linked with potentially aggressive tumor phenotype in invasive breast carcinoma.

Keywords: Hormone receptors; human epidermal growth-factor receptor 2/neu; imprint cytology; pAkt

References

  1. J Biol Chem. 1997 Nov 28;272(48):30491-7 - PubMed
  2. J Clin Oncol. 2001 Sep 15;19(18):3808-16 - PubMed
  3. J Clin Oncol. 2004 Oct 15;22(20):4217-26 - PubMed
  4. Breast. 2003 Aug;12 Suppl 2:S2-19 - PubMed
  5. Science. 1987 Jan 9;235(4785):177-82 - PubMed
  6. Int J Cancer. 2006 Jan 15;118(2):284-9 - PubMed
  7. Eur J Cancer. 2005 May;41(7):1017-25 - PubMed
  8. Ann Oncol. 2008 Feb;19(2):315-20 - PubMed
  9. Oncol Rep. 2007 Jul;18(1):139-43 - PubMed
  10. J Pathol. 2005 Oct;207(2):139-46 - PubMed
  11. Genes Dev. 1999 Nov 15;13(22):2905-27 - PubMed
  12. Br J Cancer. 2004 Jun 14;90(12):2344-8 - PubMed
  13. Mod Pathol. 2004 Jan;17(1):15-21 - PubMed
  14. J Clin Oncol. 1999 Jul;17(7):1983-7 - PubMed
  15. Adv Exp Med Biol. 2003;532:253-68 - PubMed
  16. Nature. 2012 Apr 18;486(7403):346-52 - PubMed
  17. J Mammary Gland Biol Neoplasia. 1998 Jan;3(1):85-94 - PubMed
  18. Breast Cancer Res. 2003;5(2):R37-44 - PubMed
  19. FEBS Lett. 1997 Jun 23;410(1):83-6 - PubMed
  20. J Biol Chem. 1997 Dec 12;272(50):31515-24 - PubMed
  21. Nat Clin Pract Oncol. 2006 May;3(5):269-80 - PubMed
  22. Cell Signal. 2002 May;14(5):381-95 - PubMed
  23. Exp Cell Res. 1999 Nov 25;253(1):210-29 - PubMed

Publication Types